Evidence map›Paper›PMID 33311984›Full record

ArticleBreast cancer : basic and clinical research2020

miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker.

Sara S Oltra, Maria Peña-Chilet, Maria T Martinez, Eduardo Tormo, Juan Miguel Cejalvo, Joan Climent, Pilar Eroles, Ana Lluch, Gloria Ribas

Open access · goldAbstract read
In one paragraph

Article in Breast cancer : basic and clinical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sara S OltraMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
Maria Peña-ChiletMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
Maria T MartinezMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
Eduardo TormoMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
Juan Miguel CejalvoMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
Joan ClimentMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
Pilar ErolesMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
Ana LluchMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
Gloria RibasMedical Oncology and Hematology Unit, INCLIVA Health Research Institute, INCLIVA Biomedical Research Institute, Valencia, Spain.
INCLIVA Health Research Institute · ESCentro de Investigación Biomédica en Red de Cáncer · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe study of breast cancer nearly always involves patients close to menopause or older. Therefore, young patients are mostly underrepresented. Our aim in this study was to demonstrate biological differences in breast cancer of young people using as a model available cell lines derived from people with breast cancer younger than 35 years.

methodsGlobal miRNA expression was analyzed in breast cancer cells from young (HCC1500, HCC1937) and old patients (MCF-7, MDA-MB-231, HCC1806, and MDA-MB-468). In addition, it was compared with same type of results from patients.

resultsWe observed a differential profile for 155 miRNAs between young and older cell lines. We identified a set of 24 miRNA associated with aggressiveness that were regulating pluripotency of stem cell-related pathways. Combining the miRNA expression data from cell lines and breast cancer patients, 132 miRNAs were differently expressed between young and old samples, most of them previously found in cell lines. MiR-23a-downregulation was also associated with poor survival in young patients.

conclusionsOur results suggest that HCC1500 and HCC1937 cell lines could be suitable cellular models for breast cancer affecting young women. The miR-23a-downregulation could have a potential role as a poor prognosis biomarker in this age group.

Indexed as

Breast cancer cell modelbreast cancer young womenCell linesmicroRNAs

Identifiers

PMID33311984
PMCPMC7716059
OpenAlexW3107358323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.